作者: Richard A. Revia , Miqin Zhang
DOI: 10.1016/J.MATTOD.2015.08.022
关键词: Magnetite Nanoparticles 、 Drug delivery 、 Diagnosis treatment 、 Biocompatible material 、 Contrast enhancement 、 Cancer 、 Nanotechnology 、 Nanoparticle 、 Treatment monitoring 、 Materials science
摘要: The development of nanoparticles (NPs) for use in all facets of oncological disease detection and therapy has shown great progress over the past two decades. NPs have been tailored for use as contrast enhancement agents for imaging, drug delivery vehicles, and most recently as a therapeutic component in initiating tumor cell death in magnetic and photonic ablation therapies. Of the many possible core constituents of NPs, such as gold, silver, carbon nanotubes, fullerenes, manganese oxide, lipids, micelles, etc., iron oxide (or …